Compare Davita Inc (DVA) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nasdaq Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Nasdaq Inc trades at $92.6 (market cap $51.63B). The key difference: Nasdaq Inc is far larger — about 4.6× Davita Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Nasdaq Inc for 125 Days on average.
| DVA | NDAQ | |
|---|---|---|
Market Cap | $11.29B | $51.63B |
Volume | 582,204 | 2,668,175 |
Sector | Health | Financials |
52-Week High | $240.96 | $100.98 |
52-Week Low | $103.87 | $76.85 |
Typical Hold Time | 113 Days | 125 Days |
Enterprise Value | $24.01B | $58.09B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Nasdaq (NDAQ) trades at $91.93, down 0.37% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $8.26 billion and net income of $1.79 billion, yielding a net margin of 21.64%. Recent news highlights growth in its Financial Technology segment, including AI enhancements to the Calypso platform and new client adoptions like HSBC.
The outlook is positive given analyst consensus with a $110.71 price target and 61% buy ratings, though near-term technical weakness and high valuation ratios pose risks. Key catalysts include continued tech adoption and cross-selling, while risks involve market volatility and execution challenges in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
